Cargando…

Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy

Programmed cell death protein 1/Programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors are the most promising treatments for malignant tumors currently, but the low response rate limits their further clinical utilization. To address this problem, our group constructed an engineered...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, De-Xi, Wang, Xiao-He, Xu, Xuan, Chen, Wen-Jie, Wei, Jing, Chen, Ting-Tao, Wei, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781615/
https://www.ncbi.nlm.nih.gov/pubmed/36559282
http://dx.doi.org/10.3390/pharmaceutics14122789
_version_ 1784857117669195776
author Zhou, De-Xi
Wang, Xiao-He
Xu, Xuan
Chen, Wen-Jie
Wei, Jing
Chen, Ting-Tao
Wei, Hong
author_facet Zhou, De-Xi
Wang, Xiao-He
Xu, Xuan
Chen, Wen-Jie
Wei, Jing
Chen, Ting-Tao
Wei, Hong
author_sort Zhou, De-Xi
collection PubMed
description Programmed cell death protein 1/Programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors are the most promising treatments for malignant tumors currently, but the low response rate limits their further clinical utilization. To address this problem, our group constructed an engineered strain of VNP20009-Abvec-Igκ-mPD-1 [V-A-mPD-1 (mPD-1, murine PD-1)] to combine oncolytic bacterial therapy with immunotherapy. Further, we evaluated its growth performance and mPD-1 expression ability in vitro while establishing the melanoma mice model to explore its potential anti-cancer effects in tumor therapy. Our results indicated that the V-A-mPD-1 strain has superior growth performance and can invade B16F10 melanoma cells and express PD-1. In addition, in the melanoma mice model, we observed a marked reduction in tumor volume and the formation of a larger necrotic area. V-A-mPD-1 administration resulted in a high expression of mPD-1 at the tumor site, inhibiting tumor cell proliferation via the down-regulation of the expression of rat sarcoma (Ras), phosphorylated mitogen-activated protein kinase (p-MEK)/MEK, and phosphorylated extracellular signal-regulated kinase (p-ERK)/ERK expression significantly inhibited tumor cell proliferation. Tumor cell apoptosis was promoted by down-regulating phosphoinositide 3 kinase (PI3K) and protein kinase B (AKT) signaling pathways, as evidenced by an increased Bcl-2-associated X protein/B cell lymphoma-2 (Bax/Bcl-2) expression ratio. Meanwhile, the expression levels of systemic inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), were substantially reduced. In conclusion, our research demonstrated that V-A-mPD-1 has an excellent anti-tumor effect, prompting that the combined application of microbial therapy and immunotherapy is a feasible cancer treatment strategy.
format Online
Article
Text
id pubmed-9781615
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97816152022-12-24 Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy Zhou, De-Xi Wang, Xiao-He Xu, Xuan Chen, Wen-Jie Wei, Jing Chen, Ting-Tao Wei, Hong Pharmaceutics Article Programmed cell death protein 1/Programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors are the most promising treatments for malignant tumors currently, but the low response rate limits their further clinical utilization. To address this problem, our group constructed an engineered strain of VNP20009-Abvec-Igκ-mPD-1 [V-A-mPD-1 (mPD-1, murine PD-1)] to combine oncolytic bacterial therapy with immunotherapy. Further, we evaluated its growth performance and mPD-1 expression ability in vitro while establishing the melanoma mice model to explore its potential anti-cancer effects in tumor therapy. Our results indicated that the V-A-mPD-1 strain has superior growth performance and can invade B16F10 melanoma cells and express PD-1. In addition, in the melanoma mice model, we observed a marked reduction in tumor volume and the formation of a larger necrotic area. V-A-mPD-1 administration resulted in a high expression of mPD-1 at the tumor site, inhibiting tumor cell proliferation via the down-regulation of the expression of rat sarcoma (Ras), phosphorylated mitogen-activated protein kinase (p-MEK)/MEK, and phosphorylated extracellular signal-regulated kinase (p-ERK)/ERK expression significantly inhibited tumor cell proliferation. Tumor cell apoptosis was promoted by down-regulating phosphoinositide 3 kinase (PI3K) and protein kinase B (AKT) signaling pathways, as evidenced by an increased Bcl-2-associated X protein/B cell lymphoma-2 (Bax/Bcl-2) expression ratio. Meanwhile, the expression levels of systemic inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), were substantially reduced. In conclusion, our research demonstrated that V-A-mPD-1 has an excellent anti-tumor effect, prompting that the combined application of microbial therapy and immunotherapy is a feasible cancer treatment strategy. MDPI 2022-12-13 /pmc/articles/PMC9781615/ /pubmed/36559282 http://dx.doi.org/10.3390/pharmaceutics14122789 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhou, De-Xi
Wang, Xiao-He
Xu, Xuan
Chen, Wen-Jie
Wei, Jing
Chen, Ting-Tao
Wei, Hong
Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy
title Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy
title_full Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy
title_fullStr Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy
title_full_unstemmed Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy
title_short Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy
title_sort anti-tumor effects of engineered vnp20009-abvec-igκ-mpd-1 strain in melanoma mice via combining the oncolytic therapy and immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781615/
https://www.ncbi.nlm.nih.gov/pubmed/36559282
http://dx.doi.org/10.3390/pharmaceutics14122789
work_keys_str_mv AT zhoudexi antitumoreffectsofengineeredvnp20009abvecigkmpd1straininmelanomamiceviacombiningtheoncolytictherapyandimmunotherapy
AT wangxiaohe antitumoreffectsofengineeredvnp20009abvecigkmpd1straininmelanomamiceviacombiningtheoncolytictherapyandimmunotherapy
AT xuxuan antitumoreffectsofengineeredvnp20009abvecigkmpd1straininmelanomamiceviacombiningtheoncolytictherapyandimmunotherapy
AT chenwenjie antitumoreffectsofengineeredvnp20009abvecigkmpd1straininmelanomamiceviacombiningtheoncolytictherapyandimmunotherapy
AT weijing antitumoreffectsofengineeredvnp20009abvecigkmpd1straininmelanomamiceviacombiningtheoncolytictherapyandimmunotherapy
AT chentingtao antitumoreffectsofengineeredvnp20009abvecigkmpd1straininmelanomamiceviacombiningtheoncolytictherapyandimmunotherapy
AT weihong antitumoreffectsofengineeredvnp20009abvecigkmpd1straininmelanomamiceviacombiningtheoncolytictherapyandimmunotherapy